Erasca, Inc.
14.39USD
+0.3500 (+2.49%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ERAS.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.13▼ | -$0.12 | 2 | 5 |
| Next quarter | -$0.13▲ | -$0.14 | 4 | 4 |
| Current year | -$0.98▼ | -$0.97 | 3 | 6 |
| Next year | -$0.62▼ | -$0.57 | 2 | 7 |
Beat in 1 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.11 | -$0.14 | -0.03 (-25.3%) |
| 2026-03-31 | -$0.23 | -$0.6 | -0.37 (-166.0%) |
| 2025-12-31 | -$0.11 | -$0.1 | +0.01 (+6.0%) |
| 2025-09-30 | -$0.11 | -$0.11 | -0.00 (-4.5%) |
55 ratings from 14 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| B of A Securities | Maintained | Neutral | $18 $20 | Aug 14, 2026 |
| Guggenheim | Maintained | Buy | $20 $21 | Aug 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $18 $22 | Aug 12, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $12 $21 | Jul 20, 2026 |
| B of A Securities | Maintained | Neutral | $16 $18 | Jul 14, 2026 |
| B of A Securities | Upgraded from Underperform | Neutral | $9 $16 | Jun 4, 2026 |
| Mizuho | Maintained | Outperform | $28 $26 | May 12, 2026 |
| Stifel | Maintained | Buy | $20 $30 | Apr 27, 2026 |
| JP Morgan | Maintained | Overweight | $24 $25 | Mar 18, 2026 |
| Guggenheim | Maintained | Buy | $12 $20 | Mar 16, 2026 |
| Piper Sandler | Maintained | Overweight | $11 $18 | Mar 13, 2026 |
| Mizuho | Maintained | Outperform | $16 $19 | Mar 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $15 $20 | Mar 13, 2026 |
| Clear Street | Maintained | Buy | $11 $20 | Mar 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $11 $15 | Jan 26, 2026 |
| Piper Sandler | Maintained | Overweight | $5 $11 | Jan 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $6 $11 | Jan 13, 2026 |
| Piper Sandler | Initiated | Overweight | $5 | Jan 7, 2026 |
| Mizuho | Maintained | Outperform | $4 $5 | Dec 9, 2025 |
| Guggenheim | Maintained | Buy | $3 $5 | Nov 14, 2025 |
| Stifel | Initiated | Buy | $4 | Oct 16, 2025 |
| B of A Securities | Downgraded from Buy | Underperform | $4 $1 | Sep 3, 2025 |
| Morgan Stanley | Downgraded from Overweight | Equal-Weight | $4 $2 | Aug 18, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $6 | Apr 30, 2025 |
| Raymond James | Initiated | Outperform | $5 | Mar 26, 2025 |
8 filings from 3 insiders · 1 buy / 1 sell over 6m
Officers and directors of ERAS, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| GARNER EBUN SOfficer | Sell | 80.0k | $16.40 | $1.31M | Apr 1, 2026 |
| GARNER EBUN SOfficer | Exercise | 80.0k | $1.70 | $136k | Apr 1, 2026 |
| MORRIS SHANNON R. M.D., PH.D.Officer | Sell | 20.0k | $15.04 | $301k | Mar 4, 2026 |
| MORRIS SHANNON R. M.D., PH.D.Officer | Exercise | 20.0k | $1.70 | $34k | Mar 4, 2026 |
| GARNER EBUN SGeneral Counsel | Sell | 120.0k | $5.59 | $671k | Jan 7, 2026 |
| GARNER EBUN SGeneral Counsel | Exercise | 120.0k | $1.70 | $204k | Jan 7, 2026 |
| GARNER EBUN SGeneral Counsel | Grant | 3.9k | $3.43 | $13k | Dec 15, 2025 |
| MULTANI PRATIK SDirector | Gift | 6.2k | — | — | May 23, 2025 |
No analyst notes on ERAS yet.
Analyst Ratings
9 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 5 | 2 | 0 | 0 | Buy2.00 |
| 1 mo ago | 2 | 5 | 2 | 0 | 0 | Buy2.00 |
| 2 mo ago | 2 | 6 | 2 | 0 | 0 | Buy2.00 |
| 3 mo ago | 2 | 6 | 2 | 0 | 0 | Buy2.00 |
Members whose judged calls on ERAS have played out most reliably.
No settled calls on ERAS yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice